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Insights From a Meta-Analysis of Randomized Controlled Trials
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Giuseppe Lucisano, MSC,‡ Francesco Palma, MD,* Alfonso Tatasciore, MD,* Roberto Marchioli, MD‡
Chieti and Pisa, Italy
Objectives This meta-analysis was performed to determine the effects of various cholesterol-lowering treatments on the
risk of stroke and its relationship with the extent of cholesterol lowering.
Background Statins reduce the incidence of stroke, and it has been proposed that such effect is independent of cholesterol
lowering and is explained by alternative mechanisms.
Methods We performed a meta-analysis of randomized trials of cholesterol-lowering treatments in cardiovascular disease re-
porting on stroke, involving 266,973 patients investigated and a cumulative 946,582 person-years of exposure, and a
meta-regression analysis of the extent of stroke reduction as a function of changes in total cholesterol.
Results The odds ratio (OR) for the incidence of stroke in actively treated groups versus controls was 0.88 (95% confi-
dence interval: 0.83 to 0.94, p  0.001). No treatment affected fatal strokes. Whereas statins decreased the
risk of total stroke significantly (OR: 0.85, 95% confidence interval: 0.78 to 0.92; p  0.001), the benefit of non-
statin interventions was smaller and not statistically significant (diet OR: 0.92, fibrates OR: 0.98, other treatments
OR: 0.81). We found a significant relationship between percent reduction of total (and low-density lipoprotein) choles-
terol and percent reduction of total strokes (p  0.0017), with each 1% reduction of total cholesterol predicting a
0.8% relative risk reduction of stroke. We found no significant association between stroke reduction and changes of
high-density lipoprotein cholesterol levels, and inconsistent associations with reduction of triglycerides.
Conclusions Among cholesterol-lowering treatments, statins are the most effective at decreasing the risk of total stroke, but
their benefit is proportional to the percent reduction of total cholesterol and low-density lipoprotein cholesterol.
No lipid-lowering intervention was associated with a reduction of fatal stroke. (J Am Coll Cardiol 2010;55:
198–211) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.07.062c
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nmple epidemiological data suggest that hypercholesterol-
mia is a powerful risk factor for coronary heart disease
CHD) and nonfatal/fatal ischemic stroke (1,2). The rela-
ionship between serum cholesterol and stroke, currently 1
f the most common causes of death and long-term severe
isability, has been in the past controversial (3,4). Recently,
he Cholesterol Treatment Trialists meta-analysis of 14
tatin trials, including 8,000 deaths, determined that a 38
g/dl reduction in low-density lipoprotein cholesterol
LDL-C) reduced the risk of total stroke by 17% (5).
lthough different cholesterol-lowering drugs or nonphar-
acological treatments significantly reduce morbidity from
HD (6–14), thus proving a causal role for cholesterol in
oronary events, it has been maintained that among
rom the *Institute of Cardiology and University Cardiology Division, “G.
’Annunzio” University, Chieti, Italy; †National Research Council (CNR) Institute
f Clinical Physiology and Fondazione G. Monasterio, Pisa, Italy; and the ‡Consor-
io Mario Negri Sud, S. Maria Imbaro, Chieti, Italy.c
Manuscript received April 27, 2009; revised manuscript received July 20, 2009,
ccepted July 27, 2009.holesterol-lowering interventions, only statins protect
gainst stroke (9,14–19), thus arguing for the clinical
elevance of statin properties unrelated to cholesterol low-
ring (“pleiotropic”) on this clinical outcome.
To avoid type II error due to the small sample size of clinical
rials testing cholesterol-lowering interventions different from
tatins, we here report on a meta-analysis of the effect of all
holesterol-lowering interventions on the occurrence of differ-
nt types of strokes, specifically on fatal and nonfatal strokes,
he types of strokes more frequently defined in clinical trials
nd of substantial clinical relevance, and a meta-regression of
he relationship between the extent of cholesterol lowering
total cholesterol [TC] being the lipid data always reported in
he various trials) and the extent of stroke reduction, including
total of 78 trials and 266,973 patients, with a mean follow-up
f 3.5 years and a cumulative exposure of 946,582 person-
ears. We specifically sought to answer these questions: 1) Is
he effect of cholesterol-lowering agents on the incidence of
troke restricted to statins, or is it also shared by other agents or
onpharmacological strategies? 2) Is there a different effect of
holesterol-lowering interventions on fatal and nonfatal
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he extent of blood lipids (TC, high-density lipoprotein cho-
esterol [HDL-C], and LDL-C) reduction?
ethods
iterature search and data abstraction. We retrieved all ran-
omized clinical trials (RCTs) reporting on cholesterol-lowering
nterventions and stroke published until April 2009. (Search
riteria and methods for data abstraction are detailed in the
nline Appendix.)
tatistical methods. Estimates of the average effect and
5% confidence intervals (CIs) of statins, fibrates, and other
holesterol-lowering interventions on serum lipids were
alculated with a random-effect assumption, according to
he Mantel-Haenszel method (20,21). However, a prelim-
nary Q test (22) for homogeneity was performed, and no
aterial evidence for heterogeneity was found.
Individual odds ratios (ORs) were estimated as the
ross-product of cell counts in the corresponding 2  2
able, with variance of natural logarithm (ln) of OR equal to
he sum of the reciprocal cell counts. For trials with no
vents, a pseudocount of 0.5 was added to each cell for these
alculations (20,21).
Sensitivity analyses were carried out to assess the strength
f the association between effects of statins on the events of
nterest and explanatory variables, such as baseline charac-
eristics of patients. Relative risk (RR) instead of OR was
sed to assess the effect of the interventions on the risk of
troke according to the risk of death of the population recruited
n each trial. This risk was estimated according to the rate of
eath observed in the control group of each study.
To further explore the relationship of cholesterol reduction
nd total stroke, a meta-regression by using inverse variance-
eighted linear regression was performed (23). The dependent
ariable in the model was the logarithm RR for total stroke as
he dependent variable against the variables discussed earlier,
nd weights in each study were the reciprocals of the variances
or the logarithm RR for stroke (24). In each trial, the percent
eduction in total serum cholesterol levels (%TC) was calcu-
ated by subtracting end-study (or mean in-study) TC from
aseline TC in treated and control groups:
%TC
TCfTCb
TCb
 100
here TCf was end-study (or mean in-study) total serum
holesterol, and TCb was baseline total serum cholesterol.
When not reported, the mean duration of follow-up
FUmean) was calculated as follows:
FUmean
AP FUmaxDP
FUmax
2
TPhere TP was the total number of patients, AP was the wumber of patients alive, DP the
umber of subjects deceased dur-
ng the study, and FUmax the
aximum follow-up.
Statistical testing for efficacy
as conducted at a 2-tailed
-level of 0.05. As to the homo-
eneity tests, an -level of 0.10
as chosen. All analyses were
erformed using the SAS soft-
are version 9.2 (SAS Institute,
nc., Cary, North Carolina).
esults
verall, 78 trials tested the effi-
acy of cholesterol-lowering in-
erventions on total, fatal, or nonfatal stroke, involving
66,973 patients, with a cumulative exposure of 946,582
erson-years (mean follow-up of 3.5 years). Four studies
andomly allocated patients to multiple arms of treatment;
or this reason, data from their control groups were used
wice in the analysis, and the total number of trials included
as raised to 82.
A total of 49 RCTs tested the efficacy of statins. The
ther 33 trials used other lipid-lowering interventions: 13
tudies tested fibrates, 7 trials tested dietary interventions,
2 studies tested other drugs, and 1 study tested surgery.
As to total stroke, 76 trials evaluated the effect of
owering cholesterol levels in 251,476 subjects on total
troke, thus raising the total number of trials included in the
nalysis to 80. The occurrence of fatal stroke was reported in
2 RCTs, and 2 actively treated groups were compared with
single control group in 4 studies, thus raising the total
umber of RCTs to 66. The occurrence of nonfatal stroke
as reported in 41 RCTs, and 2 actively treated groups were
ompared with a single control group in 3 studies. (Details
n such trials from which data abstraction was obtained are
iven in the Online Appendix.)
Tables 1 and 2 show the main characteristics of the RCTs
ncluded in the analysis. Patients included in the selected
CTs had a mean age of 61 years, and the male/female ratio
as 0.61. Smokers, diabetic patients, and hypertensive
atients were 20% (71 trials), 21% (70 trials), and 47% (64
rials), respectively. Twenty-seven percent (66 trials) and
.4% (35 trials) of patients had a history either of myocardial
nfarction or stroke, respectively. Mean pre-treatment level
f total serum cholesterol was 224 mg/dl as an average of the
ctive and control groups.
ffect of cholesterol-lowering interventions on fatal
vents. Table 3 and Figure 1A present the main results for
otal stroke. Information about total stroke was available for
23,293 patients allocated to an active cholesterol-lowering
reatment and 131,219 controls. Overall, 2,993 subjects
2.4%) suffered a stroke in the treated group as compared
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
HDL-C  high-density
lipoprotein cholesterol
LDL-C  low-density
lipoprotein cholesterol
OR  odds ratio
RCT  randomized clinical
trial
RR  relative risk
TC  total cholesterolith 3,724 (2.8%) in the control group. Cholesterol-
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211escription of Trials Selected, Demographic CharacteristicsTable 1 Description of Trials Selected, Demographic Characteristics
Trial, Year of
Publication Design* Follow-Up†
Total
Patients
Total
Stroke
Fatal
Stroke
Nonfatal
Stroke
Age, yrs
(Mean)
SMK
(%)
DM
(%)
HBP
(%)
PMI
(%)
PST
(%)
Oslo, 1966 D,op,SE 5 412 3 2 N/A 56.0 64.6 10.0 — 100 —
MRC, 1968 D,op,SE 4 393 2 2 0 — 82.5 0.0 13.0 100 —
LA, 1969 D,b,PS 8 846 38 12 26 65.5 66.4 — — 20.1 12.5
Newcastle, 1971 F,b,SE 3.6 497 1 1 0 52.5 65.0 0.0 0.0 23.0 —
Scottish, 1971 F,b,SE 3.4 717 5 5 0 52.1 56.6 0.0 — 72.9 —
VA, 1974 F,b,SE 4.5 532 60 13 N/A — — 23.5 64.5 — 16.0
CDP, 1975 F O,b,SE 6.2 5,011 161 34 N/A 52.0 37.9 5.0 20.0 100.0 2.0
Dorr, 1978 O,b,PS 1.9 1,094 1 1 0 50.5 — 13.7 16.2 6.2 0.5
WHO, 1980 F,b,PR 5.3 10,627 N/A 25 31 45.9 56.0 0.0 0.0 0.0 0.0
McCaughan, 1981 O,b,PS 1 118 0 0 0 49.8 44.6 — — 33.9 —
LRC-CPPT, 1984 O,b,PR 7.4 3,806 35 4 0 47.7 37.5 0.0 0.0 0.0 0.0
CLAS I, 1987 O,b,SE 2 188 0 0 0 54.2 0.0 0.0 0.0 — —
Helsinki, 1987 F,b,PR 5 4,081 10 10 0 47.3 36.2 2.6 14.0 0.0 0.0
Stockholm, 1988 O,op,SE 5 555 11 6 5 59.8 67.3 3.3 36.0 100.0 —
Minnesota, 1989 D,b,PR 1.1 9,057 43 43 0 48.0 — — — — —
FATS, 1990 S O,b,SE 2.7 146 0 0 0 47.3 24.4 0.0 32.8 42.6 —
POSCH, 1990 B,op,SE 9.7 838 29 3 N/A 51.0 35.0 0.0 0.0 100.0 0.0
EXCEL, 1991 S,b,PS 0.9 8,245 11 1 N/A 55.8 18.3 1.1 39.6 — 3.9
Singh, 1992 D,b,SE 1 406 3 3 0 51.3 35.4 18.0 22.0 100.0 —
Frick, 1993 F,b,SE 5 628 2 2 0 48.6 38.8 — — 9.0 —
MARS, 1993 S,b,SE 2.2 270 3 0 N/A 58.0 — 0.0 46.0 60.0 —
PMSG-CRP, 1993 S,b,SE 0.5 1,062 3 0 3 55.0 28.7 0.0 47.5 34.5 —
4S, 1994 S,b,SE 5.5 4,444 132 26 N/A 58.6 25.6 4.5 26.0 79.3 0.0
ACAPS, 1994 S,b,PR 2.8 919 5 2 3 61.7 11.9 2.3 28.8 0.0 0.0
CCAIT, 1994 S,b,SE 2 331 1 0 N/A 53.0 27.0 14.0 37.0 54.0 18.0
LR, 1994 S,b,SE 0.5 404 1 0 1 62.0 49.8 11.6 48.8 25.0 —
Lyon, 1994 D,b,SE 2.3 605 3 0 3 53.5 6.2 — 0.0 100.0 —
MAAS, 1994 S,b,SE 4 381 3 0 N/A 55.3 23.9 0.0 — 54.3 —
PLAC-I, 1994 S,b,SE 2.3 408 2 0 2 57.0 16.5 0.0 45.5 43.5 0.0
PLAC-II, 1994 S,b,SE 3 151 4 1 N/A 62.5 12.1 — 0.0 63.8 —
REGRESS, 1994 S,b,SE 2 884 2 0 2 56.2 27.7 0.1 27.8 47.4 —
KAPS, 1995 S,b,PS 3 447 6 1 5 57.4 26.2 2.5 33.1 7.6 —
CARE, 1996 S,b,SE 5 4,159 128 16 N/A 59.0 21.0 14.5 42.5 100 —
WOSCOPS, 1996 S,b,PR 4.9 6,595 97 10 N/A 55.2 44.0 1.0 15.5 0.0 0.0
CIS, 1997 S,b,SE 2.3 254 0 0 0 49.3 84.3 0.0 — — —
LOCAT, 1997 F,b,SE 2.5 395 0 0 0 59.2 — 0.0 40.0 55.2 —
PCABGT, 1997 S,op,SE 4.3 1,351 34 N/A N/A 61.5 11.3 8.6 — 49.3 —
PREDICT, 1997 S,b,SE 0.5 695 1 1 0 58.3 33.7 7.2 30.7 37.1 1.9
AFCAPS, 1998 S,b,PR 5.2 6,605 31 N/A N/A 58.0 12.4 2.4 21.9 0.0 0.0
LIPID, 1998 S,b,SE 6.1 9,014 373 49 N/A 61.5 9.6 8.7 41.7 63.8 4.1
Mas, 1999 O,b,SE 0.5 437 1 N/A N/A 58.0 32.7 17.8 82.2 — 3.9
GISSI-P, 2000 S,op,SE 1.9 4,271 39 8 31 60.0 11.9 13.6 36.5 100.0 —
SCAT, 2000 S,b,SE 4.0 460 11 9 N/A 61.0 15.0 10.9 35.2 70.4 —
VA-HIT, 2000 F,b,SE 5.1 2,531 134 12 N/A 64.0 20.5 24.5 57.0 61.0 —
BCAPS, 2001 S,b,SE 3 793 8 N/A N/A 61.8 30.8 3.0 12.1 — —
BIP, 2001 F,b,SE 6.2 3,090 149 N/A N/A 60.1 11.8 10.0 32.4 77.9 1.1
DAIS, 2001 F,b,SE 3.3 418 12 N/A N/A 56.8 14.8 100.0 51.4 — —
HATS, 2001 S,b,SE 3 160 4 0 4 53.0 24.0 16.0 49.0 55 —
ALLHAT-LLT, 2002 S,op,PR 4.8 10,355 440 109 N/A 66.4 23.2 35.1 100.0 0.0 0.0
FAST, 2002 S O,PR 2 246 0 0 0 66.3 61.2 24.2 39.1 — —
GREACE, 2002 S,op,SE 3 1,600 26 1 N/A 58.5 — 19.6 42.9 81.2 —
HPS, 2002 S,b,SE 5 20,536 1,029 215 865 64.0 14.1 29.0 41.0 41.0 —
LEADER, 2002 F,b,SE 4.6 1,568 109 22 87 68.2 37.8 17.1 — 19.8 11.7
Liem, 2002 S,b,SE 1 540 3 3 0 60.5 — — — 100.0 —
LIPS, 2002 S,b,SE 3.9 1,677 3 3 N/A 60.0 26.6 12.1 38.6 44.4 2.6Continued on next page
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January 19, 2010:198–211 Cholesterol-Lowering Interventions and Strokeowering treatment decreased the risk of total stroke by 12%
95% CI: 17% to 6%; p  0.001). The result of the
eterogeneity test between studies was statistically signifi-
ant (p  0.050).
As to the efficacy of specific cholesterol-lowering inter-
entions on total stroke, 148,296 patients were treated with
tatins or placebo and 106,216 subjects were treated with
ther interventions or placebo The effect of statins on the
isk of total stroke was statistically significant, with a 15%
ecrease of the OR (95% CI: 22% to 8%; p  0.001).
he other cholesterol-lowering interventions did not de-
rease the risk of total stroke significantly, the OR varying
rom 0.81 for drugs other than statins and fibrates to 0.92
or the POSCH (Program on the Surgical Control of the
yperlipidemias) study and diet trials. Compared with trials
esting statins, those testing other cholesterol-lowering
nterventions were fewer and more likely to be conducted in
rimary prevention, and therefore observing a lower number
f strokes. However, the lack of efficacy of the other
nterventions was mainly due to the lack of effect of fibrates
n reducing the risk of total stroke (OR: 0.98, 95% CI: 0.86
o 1.12; p  NS), as confirmed by the nonsignificant result
f the test of heterogeneity between trials when we excluded
rom the analysis trials testing fibrates, as well as by the wide
verlap of the CI for studies testing statins and studies not
ontinuedTable 1 Continued
Trial, Year of
Publication Design* Follow-Up†
Total
Patients
Total
Stroke
PROSPER, 2002 S,b,PS 3.2 5,804 266
ALERT, 2003 S,b,PS 5.1 2,102 104
ASCOT-LLA, 2003 S,b,PR 3.2 10,305 210
Mohler, 2003 S,b,SE 1 354 2
ALLIANCE, 2004 S,b,SE 4.3 2,442 74
ARBITER2, 2004 O,b,SE 1 167 1
Bae, 2004 S,b,SE 6 205 2
CARDS, 2004 S,b,PR 3.9 2,838 60
PCS, 2004 S,b,SE 5 120 7
4D, 2005 S,b,SE 4 1,255 103
FIELD, 2005 F,b,SE 5 9,795 333
Makuuchi, 2005 S,op,SE 4.5 303 6
Stone, 2005 S,b,SE 1 300 2
ASPEN primary, 2006 S,b,PR 4 1,905 56
ASPEN secondary, 2006 S,b,SE 4 505 16
SPARCL, 2006 S,b,SE 4.9 4,731 576
WHI-DM, 2006 D,op,PS 8.1 48,835 1,076
CORONA, 2007 S,b,SE 2.7 5,011 218
ARISE, 2008 O,b,SE 2 6,144 54
CCSPS, 2008 O,b,SE 4.5 4,870 N/A
GISSI-HF, 2008 S,b,SE 3.9 4,574 148
JUPITER, 2008 S,b,PR 1.9 17,802 97
OACIS lipid, 2008 S,op,SE 0.7 353 2
Design: the first letter indicates the type of lipid lowering intervention (D  diet, S  statins, F 
op open; b blind); and the last letter indicates the clinical setting (PR primary, SE seconda
ollow-up duration is indicated in italics. For full details of trial references, see Online Table 1.
DM  diabetes mellitus; HBP  high blood pressure; N/A  not available; PMI  previous myoesting fibrates. aInformation on fatal stroke was available from 66 trials
Fig. 1B) for a total of 102,799 patients allocated to active
holesterol-lowering treatment and 110,822 controls.
ipid-lowering interventions did not decrease the risk of
atal stroke (OR: 0.99, 95% CI: 0.88 to 1.11; p  0.780);
he heterogeneity test between studies was not statistically
ignificant. Similarly, neither statins (OR: 0.98, p  0.832)
or other cholesterol-lowering interventions decreased the
isk of fatal stroke.
Information on nonfatal stroke was available from 44
rials (Fig. 1C) for a total of 75,473 patients allocated to
ctive cholesterol-lowering treatment and 85,074 controls.
holesterol-lowering interventions decreased the risk of
onfatal stroke significantly, by 13% (95% CI: 19% to
6%; p  0.001), and the heterogeneity test between
tudies was statistically significant (p  0.006). Nonfatal
troke was indeed significantly reduced by statins (OR: 0.81,
5% CI: 0.74 to 0.89, p  0.001), but not by the other
holesterol-lowering interventions.
We performed sensitivity analyses by assessing the
fficacy of cholesterol-lowering treatments in various
ubgroups of trials (Online Table 3). We found no
eterogeneity in the efficacy of cholesterol-lowering in-
erventions across a number of characteristics of the
tudies, including study duration and year of publication,
l
e
Nonfatal
Stroke
Age, yrs
(Mean)
SMK
(%)
DM
(%)
HBP
(%)
PMI
(%)
PST
(%)
235 75.4 26.8 10.7 61.9 13.4 —
N/A 50.0 18.5 18.8 74.9 3.1 5.8
N/A 63.0 32.7 24.6 100.0 0.0 0.0
1 67.8 41.3 16.9 — — —
N/A 61.2 19.5 22.1 — 57.8 6.6
N/A 67.5 10.2 27.5 74.9 49.7 —
2 60.0 41.5 29.8 48.3 12.2 —
50 62.0 22.2 100.0 83.8 0.0 0.0
N/A 59.6 67.5 17.5 59.2 — —
65 65.7 8.6 100.0 — 17.6 —
N/A 62.2 9.4 100.0 56.6 5.0 3.5
N/A 58.9 41.9 33.3 51.5 62.0 —
N/A — 0.0 16.0 63.6 39.3 —
N/A 60.5 13.2 100.0 52.3 0.0 0.0
N/A 63.2 9.7 100.0 65.5 78.2 —
527 62.7 19.2 16.7 61.9 30.9 69.1
935 62.3 6.7 — 42.9 1.9 1.1
197 73.0 8.6 29.5 63.4 59.9 12.4
54 65.0 13.5 37.0 72.0 72.0 —
N/A 58.9 34.5 12.5 55.5 100.0 —
86 68.0 14.1 26.1 54.3 — 4.5
88 66.0 15.8 0.0 57.3 0.0 0.0
N/A 63.2 57.4 31.7 47.6 100.0 7.3
, O  other drugs, B  ileal bypass or other surgery); the second letter indicates the study design
primary and secondary). †Follow-up indicates mean duration (year); in its absence, the maximum
infarction; PST  previous stroke; SMK  smoking status.Fata
Strok
36
31
N/A
1
N/A
N/A
0
6
N/A
40
N/A
1
N/A
N/A
N/A
65
150
67
0
25
67
N/A
N/A
fibrates
ry, PSverage age of the population recruited in the studies,
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211escription of Trials Selected, Lipid ParametersTable 2 Description of Trials Selected, Lipid Parameters
Trial, Year of
Publication
TC TG LDL-C HDL-C Non-HDL-C
mg/dl % mg/dl % mg/dl % mg/dl % mg/dl %
Oslo, 1966 296.0 13.9 — — — — — — — —
MRC, 1968 272.5 13.2 — — — — — — — —
LA, 1969 233.5 18.5 — — — — — — — —
Newcastle, 1971 249.7 9.3 — — — — — — — —
Scottish, 1971 272.2 8.6 — — — — — — — —
VA, 1974 241.5 6.3 168.0 22.8 — — — — — —
CDP, 1975 250.8 8.2 266.0 24.2 — — — — — —
Dorr, 1978 307.5 9.5 252.0 1.8 — — — — — —
WHO, 1980 248.0 9.1 — — — — — — — —
McCaughan, 1981 305.7 8.0 232.2 — — — — — — —
LRC-CPPT, 1984 279.8 4.9 154.8 3.8 204.9 7.7 44.4 2.5 235.4 9.5
CLAS I, 1987 244.5 22.3 152.5 18.7 170.0 37.9 44.2 34.7 200.4 34.9
Helsinki, 1987 269.8 10.0 176.0 35.4 188.7 10.7 47.4 11.2 222.4 14.5
Stockholm, 1988 248.3 13.0 208.6 19.0 160.6 — 47.9 — 200.4 —
Minnesota, 1989 207.0 13.8 116.5 11.2 — — — — — —
FATS, 1990 266.7 24.4 212.4 33.3 183.2 31.1 37.9 19.2 228.8 31.5
POSCH, 1990 250.6 25.8 203.3 15.7 178.4 35.5 40.2 7.2 210.5 32.1
EXCEL, 1991 257.9 23.7 155.5 17.8 179.8 32.4 45.0 6.0 212.9 30.0
Singh, 1992 227.0 5.9 173.4 9.0 168.6 6.8 43.5 9.5 183.5 9.8
Frick, 1993 270.1 8.5 183.3 38.5 188.1 7.1 46.3 8.6 223.8 12.0
MARS, 1993 231.6 30.4 159.4 25.5 152.7 37.4 42.7 5.7 188.9 38.6
PMSG-CRP, 1993 264.1 18.3 160.8 10.8 180.2 26.3 44.2 5.3 219.9 23.1
4S, 1994 260.4 26.0 132.9 17.0 188.0 36.0 45.5 7.0 215.0 32.7
ACAPS, 1994 235.3 14.6 139.7 11.6 155.6 21.5 52.0 4.8 183.4 20.0
CCAIT, 1994 249.5 19.6 195.0 11.9 172.5 27.4 41.3 4.3 208.2 24.0
LR, 1994 203.0 32.0 — — 128.0 36.3 38.0 — 165.0 —
Lyon, 1994 250.4 0.3 183.8 17.8 174.9 2.0 45.0 2.6 205.4 0.3
MAAS, 1994 246.8 22.7 167.0 17.6 170.9 31.4 42.7 9.1 204.1 29.1
PLAC-I, 1994 231.0 21.0 166.0 17.0 164.0 29.0 41.0 5.1 190.0 26.6
PLAC-II, 1994 234.9 21.6 171.1 1.9 165.9 29.6 41.4 2.8 193.5 25.7
REGRESS, 1994 233.0 19.4 158.1 12.7 166.2 26.9 35.9 8.6 197.1 24.5
KAPS, 1995 258.7 22.4 150.4 11.7 189.2 32.7 46.3 0.0 212.4 27.3
CARE, 1996 209.0 20.0 155.5 14.0 139.0 28.0 39.0 5.0 170.0 25.9
WOSCOPS, 1996 272.0 20.0 163.0 12.0 192.0 26.0 44.0 5.0 228.0 24.6
CIS, 1997 241.9 28.5 — 28.0 166.0 35.0 44.0 6.1 197.9 36.3
LOCAT, 1997 199.9 10.6 145.3 40.6 139.6 9.8 31.5 14.1 168.4 15.2
PCABGT, 1997 226.8 18.0 159.9 8.9 155.5 25.6 39.3 4.7 187.6 22.7
PREDICT, 1997 229.5 17.9 139.5 18.7 156.0 24.5 47.0 6.4 182.5 24.3
AFCAPS, 1998 225.8 19.3 167.5 12.7 153.5 26.5 37.2 4.6 188.6 24.0
LIPID, 1998 218.0 18.0 140.0 11.0 150.0 25.0 36.0 5.0 182.0 22.5
Mas, 1999 255.1 16.9 190.3 22.8 198.4 25.1 39.8 74.7 215.3 34.0
GISSI-P, 2000 229.3 7.9 166.2 4.7 151.7 11.8 45.7 0.6 183.6 10.3
SCAT, 2000 200.0 24.1 160.2 20.9 129.8 34.2 37.9 4.1 162.2 30.7
VA-HIT, 2000 175.0 2.9 160.5 31.7 111.5 0.8 32.0 3.1 143.0 4.2
BCAPS, 2001 236.2 13.0 102.5 — 161.2 23.0 53.2 — 183.0 —
BIP, 2001 212.5 4.7 145.0 25.2 148.5 5.2 34.6 14.5 177.9 8.4
DAIS, 2001 215.1 11.0 221.7 30.0 131.5 6.9 39.8 5.2 175.3 14.6
HATS, 2001 196.8 26.1 211.5 38.8 124.9 33.4 31.2 20.0 165.5 34.2
ALLHAT-LLT, 2002 223.7 10.4 151.7 5.7 145.5 15.1 47.5 5.5 176.2 14.7
FAST, 2002 253.6 23.6 145.8 19.8 167.5 23.8 56.9 12.6 196.7 16.6
GREACE, 2002 256.0 32.0 181.0 28.0 179.5 41.0 39.0 5.0 217.0 38.5
HPS, 2002 227.8 20.3 185.8 14.3 131.3 29.4 40.9 2.8 186.9 25.4
LEADER, 2002 216.2 7.2 188.5 10.3 130.7 5.0 43.3 6.2 173.0 10.5
Liem, 2002 206.6 22.0 146.0 22.0 137.1 29.9 46.3 4.1 160.3 29.6Continued on next page
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January 19, 2010:198–211 Cholesterol-Lowering Interventions and Strokerevalence of prior myocardial infarction, inclusion of pa-
ients with diabetes mellitus, heart failure, and baseline
evels of TC, triglycerides, and HDL-C (Online Appendix).
We carried out a weighted linear regression of the log RR
or total stroke against the percent of TC reduction as the
xplanatory variable (Fig. 2), which yielded the following
quation:
loge(total stroke RR) 0.00518 0.00793(% TC reduction)
The regression coefficient for percent TC reduction was
ignificantly different from zero (p 0.0017). This equation
ndicates that some benefit from cholesterol-lowering inter-
ention on the risk of stroke can be expected when the
ercent reduction of serum cholesterol is 2% to 3%, the
linical benefit becoming statically significant (see the 95%
onfidence boundary detaching from the unity line in Fig. 2)
hen TC is reduced by 8%. Cholesterol reductions of
0%, 20%, and 30% yield 7.1%, 14.2%, and 20.8% reduc-
ions in the probability of stroke, respectively. In other
ords, the relative risk of stroke was significantly decreased
y 0.8% for each 1% reduction of TC. However, the R2
alue of the weighted linear regression was only 0.1225,
ontinuedTable 2 Continued
Trial, Year of
Publication
TC TG
mg/dl % mg/dl %
LIPS, 2002 199.5 19.0 160.0 0.0
PROSPER, 2002 220.0 19.0 132.7 13.0
ALERT, 2003 249.1 19.2 194.7 6.0
ASCOT-LLA, 2003 211.6 21.8 146.5 15.8
Mohler, 2003 205.0 26.8 191.3 29.5
ALLIANCE, 2004 225.5 8.8 197.5 6.1
ARBITER2, 2004 157.5 3.8 163.0 8.3
Bae, 2004 191.5 18.0 188.0 13.7
CARDS, 2004 206.8 26.0 171.7 19.0
PCS, 2004 200.3 8.5 142.9 5.6
4D, 2005 219.0 29.4 264.0 16.9
FIELD, 2005 194.4 6.8 153.6 23.6
Makuuchi, 2005 214.1 8.9 160.3 19.3
Stone, 2005 227.7 20.4 171.7 21.0
ASPEN prim, 2006 195.0 18.4 144.8 12.0
ASPEN sec, 2006 189.5 18.0 149.3 21.2
SPARCL, 2006 211.9 28.5 143.7 23.9
WHI-DM, 2006 224.1 0.9 139.9 0.2
CORONA, 2007 206.8 32.5 177.0 23.6
ARISE, 2008 — — — —
CCSPS, 2008 207.5 13.5 164.0 20.7
GISSI-HF, 2008 193.5 17.0 143.5 5.6
JUPITER, 2008 185.5 31.6 118.0 16.1
OACIS lipid, 2008 220.0 — 117.0 —
or full details of trial references, see Online Table 2.
% change (percent) in blood lipids due to the intervention: positive values are blood lipids red
reated/controlled low-density lipoprotein cholesterol at baseline; non–HDL-Cmean treated/con
reated/controlled total blood cholesterol at baseline; TG  mean treated/controlled triglyceridesuggesting that, although statistically significant (and clin- dcally relevant), the decrease of TC does not explain most of
he variability in the incidence of stroke, which is clearly
nfluenced by many other relevant factors.
ultivariable linear regression analysis of lipid variables
n relation with stroke. We performed univariable and
ultivariable linear regression analyses having the relative
isk of stroke and lipid variables as outcome and dependent
ariables, respectively (Tables 4 and 5). Although the
elationship between TC at baseline and the risk of stroke
isappeared in the fully adjusted multivariable models, a
trong, inverse relationship was found between HDL-C
easured at baseline on the one hand, and the change of
elative risk of stroke on the other, at both the univariable
nd the multivariable analyses, indicating that the associa-
ion between low levels of HDL-C and the risk of stroke
as not eliminated by the interventions tested (Table 4).
The univariable analysis showed that a 10% reduction of
otal blood cholesterol (TC, first row of Table 4) was
ignificantly associated with 8% RR reduction of total stroke.
uch relationship persisted when we adjusted the analysis for
ndividual blood lipids measured at baseline, for all baseline
ipids (Models 1, 2, and 3), and when we adjusted separately
or changes of triglycerides and HDL-C (Models 5 and 6). Of
ote, a further adjustment by including statins as an indepen-
LDL-C HDL-C Non-HDL-C
g/dl % mg/dl % mg/dl %
31.5 22.1 37.5 0.2 162.0 18.5
46.7 39.2 50.2 5.0 169.8 35.9
58.3 32.0 52.2 1.0 196.9 24.2
32.8 31.8 50.6 1.8 161.0 29.2
25.0 40.0 46.8 4.3 158.3 35.9
46.5 10.7 40.5 0.1 185.0 10.5
89.0 5.4 39.5 20.5 118.0 2.0
17.5 26.0 37.5 5.6 154.1 23.6
17.0 40.0 54.3 1.0 152.5 35.5
28.5 11.9 43.2 1.1 157.2 11.1
23.0 41.2 36.0 8.3 183.0 36.8
18.5 5.6 42.5 0.9 151.9 8.9
41.3 14.3 41.4 5.8 172.7 12.4
48.0 22.9 44.8 2.3 182.9 25.7
14.0 30.0 47.5 2.3 147.5 25.2
12.5 26.4 43.0 2.6 146.5 23.9
33.2 41.2 50.0 2.2 161.9 38.1
33.8 2.2 59.3 0.3 164.9 1.1
36.5 46.0 47.5 4.2 159.3 43.6
87.3 — 44.8 — — —
29.0 20.2 46.0 4.3 161.5 18.5
18.0 27.1 47.5 0.0 146.0 22.6
08.0 50.0 49.0 0.0 136.5 42.9
48.0 15.8 48.5 — 171.5
HDL-Cmean treated/controlled high-density lipoprotein cholesterol at baseline; LDL-Cmean
on–high-density lipoprotein cholesterol at baseline; prim primary; sec secondary; TCmean
eline.m
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
uction;ent variable made such a relationship disappear, thus con-
RC
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211esults, OR, and 95% CI for Total Stroke in Single Randomized Controlledlinical Trials Testing Efficacy of Statins, Fibrates, and Other InterventionsTable 3 Resul s, OR, and 95% CI for Total Stroke in Single Ra domized ControlledClinical Trials Testing Efficacy of Statins, Fibrates, and Other Interventions
Trial
TC %
Reduction
Mean (SD)
Total Stroke
p Value
Het-Within
p Value
Het-Between
OR (95% CI)
Treatment/Control
All Trials
Treated Controls
Trial
Open 11 14.4 (9.0)* 715/29,758 953/39,508 0.605 0.023 0.97 (0.88–1.07)
Blind 67 17.2 (8.5)* 2,278/93,370 2,771/91,549 0.290 0.87 (0.81–0.93)
† 2 23.6 (0.8) 0/165 0/162
Clinical setting
Primary 13 18.3 (7.4) 486/37,355 598/37,240 0.296 0.007 0.80 (0.69–0.93)
Secondary 59 17.0 (8.9)‡ 1,854/54,590 2,277/57,836 0.654 0.85 (0.80–0.91)
Primary and secondary 8 15.1 (8.1) 653/31,348 849/36,143 0.330 1.02 (0.88–1.18)
Follow-up, yrs
2 23 18.4 (9.0)‡ 115/29,217 152/24,076 0.885 0.132 0.72 (0.56–0.92)
3 14 21.5 (9.4) 118/5,610 161/5,601 0.724 0.78 (0.61–1.00)
4–5 29 15.7 (6.8) 1,776/47,897 2,029/47,914 0.057 0.91 (0.82–1.01)
6–10 14 13.2 (8.5) 984/40,569 1,382/53,628 0.316 0.92 (0.83–1.02)
Years of studies
1980 9 10.6 (3.9) 127/4,461 236/7,830 0.192 0.139 1.00 (0.72–1.40)
1981–1990 9 16.3 (8.4) 67/9,474 61/9,367 1.000 1.09 (0.77–1.54)
1991–2000 27 18.2 (7.9) 456/30,658 574/25,694 0.959 0.79 (0.70–0.90)
2000 35 18.1 (9.4)‡ 2,343/78,700 2,853/88,328 0.020 0.89 (0.82–0.98)
Age, yrs
60 40 16.5 (8.0) 406/36,487 573/34,828 0.931 0.891 0.88 (0.77–1.01)
60 37 17.9 (9.3)‡ 2,547/86,142 3,127/95,830 0.042 0.87 (0.81–0.95)
† 3 13.3 (7.1) 40/664 24/561
MI, %
No 10 17.7 (8.0) 464/32,649 577/32,562 0.146 0.107 0.78 (0.66–0.94)
50 26 16.8 (8.8) 1,655/47,991 2,040/57,616 0.098 0.94 (0.84–1.06)
50 30 16.2 (9.2)‡ 709/27,475 980/30,806 0.904 0.82 (0.74–0.91)
† 14 18.7 (7.5) 165/15,178 127/10,235
Diabetes mellitus
No 15 19.7 (8.7) 73/13,598 107/13,611 0.662 0.195 0.70 (0.52–0.96)
Yes 57 17.1 (8.3)‡ 2,447/84,148 2,921/82,375 0.301 0.88 (0.82–0.94)
† 8 11.7 (8.7) 473/25,547 696/35,233
Previous stroke, %
No 13 19.2 (7.6) 534/35,497 670/35,404 0.259 0.030 0.78 (0.68–0.91)
5 12 12.6 (7.1) 997/43,542 1,352/51,714 0.565 0.97 (0.89–1.05)
5 9 17.6 (9.7)* 573/8,962 609/8,954 0.041 0.99 (0.80–1.23)
† 46 17.5 (8.8)* 889/35,292 1,093/35,147
Heart failure
No 78 16.8 (8.5)‡ 2,808/118,494 3,543/126,433 0.361 0.163 0.87 (0.82–0.93)
Yes 2 24.8 (11.0) 185/4,799 181/4,786 0.110 1.04 (0.74–1.46)
Death risk, control group§
Low, 1%/yr 23 19.7 (7.6) 112/20,636 121/15,580 0.966 0.023 0.92 (0.70–1.20)
Mod, 1%–3.5%/yr 35 17.0 (8.9)‡ 1,961/65,975 2,365/65,898 0.136 0.84 (0.78–0.91)
High, 3.5%/yr 19 14.7 (83) 483/16,652 591/19,955 0.507 1.00 (0.89–1.13)
† 3 12.0 (10.8) 437/20,030 647/29,786
TC level, mg/dl
200 12 15.7 (10.0) 372/20,099 433/20,077 0.194 0.812 0.84 (0.68–1.03)
201–250 44 17.8 (8.1)† 2,361/77,376 2,878/86,969 0.083 0.90 (0.83–0.98)
251–270 15 19.2 (9.0) 166/15,830 308/14,254 0.833 0.84 (0.69–1.02)
270 8 10.8 (4.7) 73/6,910 72/6,853 0.899 1.00 (0.72–1.39)
† 1 * 21/3,078 33/3,066Continued on next page
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January 19, 2010:198–211 Cholesterol-Lowering Interventions and Strokerming the importance of serum cholesterol reduction in the
eduction of the risk of stroke (data not shown). Not unex-
ectedly, the amount of benefit due to TC decrease was
educed to 5% when we adjusted the analysis for changes of
riglycerides and HDL-C (Models 8 and 9), for the interrela-
ion of these serum lipids.
The results of the analyses with the percent LDL-C
hange as the explanatory variable (Table 5) gave similar
esults. At the univariable analysis, a 10% LDL-C
eduction was significantly associated with a 4% reduc-
ion of the RR of stroke. This relationship was not
ubstantially modified when we adjusted it for blood
ipids at baseline with and without percent changes of
lood lipids during the follow-up (Models 1 to 9). While
relevant relationship was found between triglyceride
hanges and the risk of total stroke in some analyses, the
ssociation of changes in HDL-C with the risk of stroke
as uncertain, namely, in the expected direction, but with
ontinuedTable 3 Continued
Trial
TC %
Reduction
Mean (SD)
Total
All
Treated
TC reduction, %
10 21 6.2 (3.5) 972/38,122
10–20 29 16.5 (3.3) 884/38,148
20 28 25.8 (4.1) 1,116/43,769
† 2 ‡ 21/3,254
Triglycerides level, mg/dl
150 20 17.3 (7.8)* 1,400/57,160
150–169 23 16.0 (8.6) 652/34,813
170 29 17.5 (9.2) 899/26,487
† 8 17.7 (9.2)* 42/4,833
Triglycerides reduction, %
10 15 11.6 (8.2) 897/36,216
10–20 29 19.2 (6.4) 1,251/61,250
20 26 18.5 (9.8) 800/20,564
† 10 14.5 (7.8)‡ 45/5,363
HDL level, mg/dl
40 20 18.3 (9.6) 465/17,519
40–44 22 17.3 (7.9)* 823/34,838
45 27 18.5 (8.8)* 1,556/61,846
† 11 10.7 (3.7) 149/9,090
Non–HDL-C level, mg/dl
160 13 17.7 (11.5) 495/22,984
160–189 30 16.9 (8.3)* 2,096/66,376
190 25 19.7 (7.5) 232/21,768
† 12 10.7 (3.7)* 170/12,168
Non–HDL-C reduction, %
20 21 8.6 (6.8) 1,085/43,036
20–30 26 19.7 (2.1) 1,029/43,825
30 17 27.1 (4.5) 700/23,211
† 16 12.5 (6.5)‡ 179/13,221
Analysis comprises 1 trial in which the reduction in total cholesterol (TC) in % was not obtainable.
he reduction in TC in % was not obtainable. §For this subgroup analysis, relative risk has been ca
CI  confidence interval; HDL-C  high-density lipoprotein cholesterol; MI  myocardial infarcto analysis being statistically significant. aiscussion
he main conclusions from this analysis of trials with
holesterol-lowering treatments and stroke are as follows.
ipid-lowering treatments reduce the cumulative inci-
ence of stroke (total and nonfatal stroke) to a statisti-
ally significant—albeit quantitatively different— extent.
he reduction of stroke by cholesterol-lowering treat-
ents appears to be proportional to the percent of
holesterol lowering, with an adjusted 0.8% of RR
eduction for any achieved 1% decrease in TC. Such
enefit seems to be due mainly to the reduction of
DL-C. The relationships between baseline levels of
DL-C and triglycerides versus the risk of stroke are not
bolished by the extent of cholesterol reduction. And finally,
he effect of cholesterol-lowering interventions appears evident
lso for nonfatal strokes, while there is still at this moment
ubstantial uncertainty—and actually no directional trend—for
e
p Value
Het-Within
p Value
Het-Between
OR (95% CI)
Treatment/ControlControls
1,319/51,203 0.724 0.001 0.98 (0.90–1.07)
954/38,081 0.696 0.93 (0.85–1.02)
1,416/38,692 0.507 0.77 (0.71–0.84)
35/3,243
1,768/66,884 0.143 0.599 0.88 (0.80–0.98)
730/29,843 0.668 0.89 (0.80–0.99)
1,164/29,658 0.241 0.91 (0.80–1.04)
62/4,834
1,101/45,973 0.879 0.001 1.01 (0.93–1.11)
1,539/56,128 0.096 0.82 (0.73–0.93)
1,015/23,804 0.913 0.88 (0.80–0.97)
69/5,314
550/17,491 0.745 0.120 0.85 (0.75–0.96)
998/29,810 0.661 0.82 (0.74–0.90)
1,919/71,542 0.093 0.90 (0.81–0.99)
257/12,376
579/22,937 0.165 0.805 0.83 (0.70–0.98)
2,605/76,041 0.110 0.89 (0.81–0.97)
250/16,799 0.901 0.92 (0.76–1.10)
290/15,442
1,351/52,784 0.950 0.019 0.96 (0.89–1.04)
1,243/38,728 0.386 0.84 (0.76–0.92)
827/23,213 0.088 0.81 (0.69–0.96)
303/16,494
not included in the between-group heterogeneity (Het) test. ‡Analysis comprises 2 trials in which
d.
d  moderate; OR  odds ratio.Strok
Trials
†Groupny favorable effect on fatal strokes.
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211Such data are new in the context of the ongoing dispute
n specific effects of statins—not related to the ability of
hese drugs to lower cholesterol—as causal in their benefi-
ial effects on stroke.
verall context for the main findings. Previous analysis
f the MRFIT (Multiple Risk Factor Intervention Trial)
oncluded that there is a strong positive association of serum
holesterol levels with death from nonhemorrhagic stroke
mong middle-aged American men, overriding a smaller
nverse relation between serum cholesterol and the risk of
eath from hemorrhagic stroke (25). The association be-
ween cholesterol and stroke, which is weaker than the
SUMMAR
ALL TRIALS
Between-Heterogeneity test χ2=9.496, df=4, P=0.0
0.0 0.
Diet 474/25417 694/35137
441/13221 505/14923
2993/123293 3724/131219
Treatment
n/N
Control
n/N
Favors tr
TOTAL STROKE
Treatment
N
Trial
7
12
80
Statins 1988/76687 2361/7160949
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76/7547 149/913311Other drugs
14/421 15/4171Bypass/
surgery
ALL TRIALS
Between-Heterogeneity test χ2=3.585, df=4, P=0.4
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FATAL STROKE
7
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66
Statins 379/55388 390/5042738
Fibrates
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Figure 1 Cumulative OR and 95% CI for Total, Fatal, and Nonfa
Cumulative odds ratios (ORs) and 95% confidence intervals (CIs) for the occurrenc
statin trials and trials involving other interventions: diet, fibrates, “other drugs,” an
trol group is plotted for each trial (the black square indicates area proportional to
zontal line). The black squares to the left of the solid vertical line indicate benefi
line. The overall result of all trials (and 95% CI) is represented by a vertical dashe
OR and 95% CI are given to the right for each subcategory analyzed.ssociation between cholesterol and myocardial infarction, cad been disputed earlier for a number of reasons (4,26–28).
ssociation studies can never—in general—prove causality,
hich may only derive from intervention trials demonstrat-
ng that cholesterol reduction leads to a reduction in stroke.
ere, the evidence from nonstatin trials in previous litera-
ure was inconclusive, whereas statin trials showed such
eduction (see the most recent meta-analysis of this kind
29]), leading one to postulate that noncholesterol-lowering
roperties of statins, generically termed “pleiotropic” effects,
ere play an important role. This conclusion might be
iased, however, for a type II error because of the smaller
ample size of nonstatin trials and the smaller extent of
LL TRIALS
1.0 1.5 2.0
0.562
0.788
<0.001
OR (95% CI) P
t Favors control
0.92
0.98
0.88
(0.69 to 1.23)
(0.86 to 1.12)
(0.83 to 0.94)
<0.0010.85 (0.78 to 0.92)
0.1550.81 (0.61 to 1.08)
0.8300.92 (0.44 to 1.93)
0.321
0.193
0.832
0.87
1.30
0.99
(0.66 to 1.15)
(0.88 to 1.92)
(0.88 to 1.11)
0.7380.98 (0.85 to 1.13)
0.8511.05 (0.61 to 1.81)
0.5650.49 (0.04 to 5.47)
0.923
0.265
<0.001
1.01
1.23
0.87
(0.89 to 1.15)
(0.85 to 1.78)
(0.81 to 0.94)
<0.0010.81 (0.74 to 0.89)
0.0590.61 (0.36 to 1.02)
troke
tal stroke (A), fatal stroke (B), and nonfatal stroke (C), each also separated for
ery. The OR of an event in the treatment group compared with that in the con-
ount of statistical information contributed by trial) along with its 95% CI (hori-
ch is significant at p  0.05 only where the entire CI is to the left of the vertical
(with a horizontal line at the bottom of each panel indicating its 95% CI). TheY - A
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January 19, 2010:198–211 Cholesterol-Lowering Interventions and Strokeions. Indeed, in our analysis, the number of patients
nvolved in nonstatin cholesterol-lowering interventions was
bout one-fifth of patients involved in statin trials. That
ustifies the need of a cumulative meta-analysis of all trials to
mprove statistical inference. In our meta-analysis, including
ata from trials with 254,512 patients, 106,216 of whom
ere involved in nonstatin trials, the point estimate of the
R for statin trials with regard to stroke (0.85) is statisti-
ally heterogeneous from that of nonstatin interventions
heterogeneity test p  0.05). However, such heterogeneity
s attributable mostly to the effect of fibrates, which,
onversely, are the weakest cholesterol-lowering interven-
ions tested (Figs. 1 and 2). Lipid-lowering interventions
ifferent from statins, but successful in cholesterol lowering,
ad a 16% relative reduction of the risk of total stroke, with
5% CIs largely overlapping with those of statin trials (Fig.
), a result compatible with the hypothesis that all sorts of
holesterol-lowering treatments can achieve some reduction
Figure 2 Meta-Regression of Relationship Between Percent T
Achieved in Cholesterol-Lowering Intervention Trials a
Meta-regression of the relationship between the percent change in total cholestero
and the relative risk (RR) of stroke (on the ordinate), on a logarithmic (ln) scale. T
dots represent trials with diet, red dots represent trials with statins, blue dots rep
represent trials with surgery. The size of the dot is proportional to the number of s
dence limits are shown in green. Note that the vast majority of nonstatin trials ach
the left indicates the point where the RR reduction becomes statistically significan
achieved higher reductions in TC. The significance of the regression is indicated inn stroke. Nonstatin trials determined a much smaller eeduction of serum cholesterol and included fewer subjects,
autioning about an overinterpretation of the nonstatistical
ignificance of the stroke reduction here found.
Conversely, the results of the meta-regression of stroke
eduction versus the change in TC achieved through the
arious interventions here demonstrate that the larger the
xtent of cholesterol reduction, the larger the protective effect
n stroke, supporting the view that the 2 phenomena are
inked. Here, we tried to run the same meta-regression
istinguishing for the effects of statins, of fibrates (also
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211aution, such R2 values are obtained from a meta-regression
nalysis not using individual patient data, which might
ntroduce an error tending to dilute the real strength of the
nderlying associations. Thus, our results in general are in
greement with the Cholesterol Treatment Trialists’ meta-
nalysis of 14 statin trials concluding on a graded relation-
hip between LDL-C lowering and a reduced risk of total
troke (“lower is better”) (5), although our quantitative
stimate of the relationship is less robust because it was not
erived from a meta-analysis of individual patient data. Our
tudy, however, also broadens the concept of the beneficial
holesterol lowering for stroke outside of specific effects
ttributable to statins.
troke reduction in relation to changes in various lipid
ubclasses. Results discussed so far pertain to the assess-
ent of TC reduction versus the reduction of stroke. Total
holesterol was chosen because it is always reported in
ipid-lowering trials. However, most of the effect of TC
eduction is now thought to be mediated by LDL-C
owering. Of note, the multivariable linear regression anal-
sis for the effect of LDL-C reduction on stroke was always
ignificant even after adjustment for baseline total and
DL-C, baseline triglycerides, and HDL-C and for the
eduction in such lipid parameters (Table 5, Model 9),
ndicating the strong relevance of LDL-C in driving the
ffect of various lipid-lowering treatments on stroke. Direc-
ionally similar reductions were also observed, however, for
eduction in non–HDL-C and triglycerides, while the
ffects of HDL-C changes were—expectedly—in the op-
osite direction (Table 5), although generally no longer
ignificant after multiple adjustments. These results also
uggest that the negative prognostic impact on stroke of
igh triglycerides and low HDL-C is not eliminated by
olely lowering LDL-C, implying the value of additive
reatments that are effective on such parameters or of statins
ith beneficial effects on HDL-C.
ensitivity analyses. We ran several sensitivity analyses to
est whether results were heterogeneous according to several
roupings. We found no heterogeneity in the efficacy of
holesterol-lowering interventions across study duration and
ear of publication, average age of the population recruited
n the studies, prevalence of prior myocardial infarction,
nclusion of patients with diabetes mellitus, heart failure,
aseline levels of TC, triglycerides, and HDL-C. The low
umbers of patients included in the trials recruiting patients
ith low (200 mg/dl) and high (270 mg/dl) total serum
holesterol levels at baseline, as well as the large overlap of
onfidence intervals, allow neither confirmation nor exclu-
ion of the existence of a linear relationship between
aseline cholesterol levels and the effects of cholesterol-
owering interventions on stroke. However, no relationship
ould be found between baseline TC levels and the loga-
ithm relative risk of total stroke by fitting a weighted linear
egression.
In assessing the efficacy of cholesterol-lowering interven-
tions according to the level of cardiovascular risk of theUn T
N N R  B B B  
Va
lu
va
lu A
Univariable and Multivariable Linear Regression Analysis for the Effect ofNon–HDL-C, LDL-C, HDL-C, and Triglyc rides Percent Reduction on To al Stroke Percent ReductionTable 5 Univariable and Mult variable Linea Regressi n A alysis for the Effect ofNon–HDL-C, LDL-C, HDL-C, and Triglycerides Percent Reduction on Total Stroke Percent Reduction
Model 0
Univariable
Model 1
Adjusted for
Baseline TC
Model 2
Adjusted for
Baseline TG
Model 3
Adjusted for
Baseline HDL-C
Model 4
Adjusted for
LDL-C
Model 5
Adjusted for
TG
Model 6
Adjusted for
HDL-C
Model 7
Adjusted for
Baseline TC,
TG, HDL-C
Model 8*
Adjusted for
LDL-C, TG,
HDL-C
Model 9*
Adjusted for Baseline
TC, TG, HDL-C and
LDL-C, TG, HDL-C
Effect of non–HDL-C
reduction (%)
No. of trials 64 64 63 64 64 64 64 63 64 63
No. of patients 224,835 224,835 224,579 224,835 224,835 224,835 224,835 224,579 224,835 224,579
R2 0.091 0.099 0.105 0.135 0.091 0.142 0.091 0.189 0.147 0.244
non–HDL-C 5% (0.016) 5% (0.016) 5% (0.011) 4% (0.056) 6% (0.644) 3% (0.274) 5% (0.018) 4% (0.038) 3% (0.257) 3% (0.196)
Effect of LDL-C
reduction (%)
No. of trials 67 67 65 67 64 64 65 64 63
No. of patients 226,389 226,389 225,727 226,389 224,835 224,835 225,727 224,835 224,579
R2 0.086 0.096 0.102 0.135 0.148 0.088 0.195 0.153 0.249
LDL-C 4% (0.016) 4% (0.015) 4% (0.012) 3% (0.045) 2% (0.200) 4% (0.021) 4% (0.026) 2% (0.196) 3% (0.148)
Effect of triglycerides
reduction (%)
No. of trials 70 70 69 65 64 64 64 64 63
No. of patients 243,875 243,875 243,619 225,390 224,835 224,835 225,134 224,835 224,579
R2 0.084 0.085 0.107 0.011 0.148 0.129 0.181 0.153 0.249
TG 7% (0.015) 7% (0.028) 8% (0.008) 0.2% (0.985) 6% (0.042) 9% (0.004) 7% (0.054) 7% (0.036) 5% (0.194)
Effect of HDL-C
reduction (%)
No. of trials 64 64 63 64 64 64 63 64 63
No. of patients 224,835 224,835 224,579 224,835 224,835 224,835 224,579 224,835 224,579
R2 0.003 0.013 0.008 0.098 0.088 0.129 0.149 0.153 0.249
HDL-C 4% (0.669) 4% (0.594) 4% (0.605) 10% (0.296) 0.2% (0.984) 5% (0.588) 13% (0.207) 5% (0.558) 17% (0.096)
Values reported are relative risk changes per 10% change of blood lipids and p values (in parentheses).  indicates percent variation of blood lipids due to the intervention. Baseline refers to blood lipid levels at baseline. Italics denote percent changes (%) over baseline
values. *Adjusted for appropriate lipid parameters; for example, in Models 8 and 9, the results for non–HDL-C (outcome variable) were not adjusted for LDL-C.
Abbreviations as in Table 2.
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Cholesterol-Lowering Interventions and Stroke January 19, 2010:198–211atients recruited in the trials by stratifying studies accord-
ng to the risk of death in the control group, we found a
omewhat higher reduction of the risk of stroke in popula-
ions at moderate risk, compared with lower or higher risk
f death. Significant heterogeneity in the results of trials was
lso found in assessing the efficacy of cholesterol-lowering
nterventions according to the study design (open or blinded
tudies), study setting (primary prevention, secondary pre-
ention, and mixed studies), and the presence of a previous
troke. We acknowledge a limited power in such subgroup
nalysis. Dietary trials, for example, included fewer subjects,
ad a limited ability in reducing serum cholesterol, and were
lso—obviously—unblinded, which contributes to hetero-
eneities found. In most cases, such heterogeneities can be
ttributable to an unbalanced presence of statin trials in the
arious subgroups.
holesterol lowering and fatal strokes. We found incon-
lusive evidence for an effect of cholesterol-lowering treat-
ents on fatal strokes. Actually, there was not even a trend
n this direction. Although the possibility of a type II error
n this context cannot be completely excluded because of the
elatively small proportions of fatal as compared with
onfatal strokes, alternative explanations exist. One expla-
ation is that hemorrhagic strokes, which are much more
ften associated with death than ischemic strokes (31,32),
ppear to be inversely related to TC (25,32), with the
ossible consequences that even a small trend toward an
ncreased incidence of hemorrhagic strokes by cholesterol-
owering treatments may largely offset the effect of the
eduction in the more frequent ischemic, more often non-
atal, strokes. This hypothesis is consistent with more recent
esults from intervention trials with statins in the HPS
Heart Protection Study) trial (33,34) and the SPARCL
Stroke Prevention by Aggressive Reduction in Cholesterol
evels) trial (35). Our plan for analyzing this hypothesis in
ur study was hampered, however, by the very low number
f trials reporting a precise diagnosis of stroke etiology,
nown to be difficult. Although an increase in hemorrhagic
troke has been only reported in the SPARCL trial (35),
nd not found when specifically sought in a short-term trial
36), this possibility cannot be dismissed looking at the
umulative evidence for fatal stroke in our analysis.
tudy limitations. First, this is a meta-analysis based on
ublished trials data, at variance from the Cholesterol
reatment Trialists meta-analysis (5), which included indi-
idual patient data but which only included statin trials
fewer than here) and many fewer patients and patient-year
xposures. Some studies did not report on the mean
ollow-up, and most studies did not report on the drop-out
f subjects at various times in the trial. Because of this, the
omputation of the mean follow-up based on our calcula-
ions (see the Methods section) is not adjusted for the
ubjects lost to follow-up or enrolled late in the trial. That
ould lead to some overestimation of the trial duration, the
onsequence of which would be some underestimation of
he treatment effects. That would reinforce, rather thaneaken, the overall message of this analysis on the effects of
ll cholesterol-lowering treatments on stroke. Second, the
ecision to include only trials longer than 6 months was
rbitrary. Although dictated by the logical need for not
ncluding trials of short duration for treatments thought to
ffect the rates of stroke only chronically, and although few
tudies had duration close to 6 months, the average duration
f statin trials was longer than that for nonstatin interven-
ions, determining a potential bias in favor of the effects of
tatins. This bias, without an analysis based on individual
atient data, could only partially be accounted for in our
ensitivity analysis. Since, however, such a bias would
ave—if anything—diluted the effect of nonstatin interven-
ions, it does not appear to appreciably hamper our here-
uggested conclusion about the effects of nonstatin inter-
entions on stroke. Third, most of our subgroup analyses are
eak for the low number of trials in some subgroups and the
ature of the analysis on cumulatively reported trial data.
herefore, all such analyses have to be taken judiciously and
onsidered confirmatory at best.
onclusions
holesterol lowering is associated with a significant reduc-
ion of stroke (total and nonfatal strokes), which appears to
xist for both statin and nonstatin cholesterol-lowering
nterventions; there appears to be a proportionality between
he reduction of cholesterol (mostly LDL-C) and the
eduction of total stroke, with an estimate of 0.8% reduction
n TC for a 1.0% reduction of the relative risk of stroke.
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